Companies present Phase II data for emerging class of Parkinson's drugs at the AAN
This article was originally published in Scrip
Executive Summary
Data from two promising adenosine A2a receptor antagonists – Vernalis/Biogen Idec's vipadenant (formerly known as BIIB014) and Synosia's SYN115 – was presented this week at the American Academy of Neurology (AAN) meeting in Toronto.